Pharma Deals Review, Vol 2004, No 48 (2004)

Font Size:  Small  Medium  Large

Merck and BMS to Co-Promote Diabetes Drug

Business Review Editor

Abstract


Bristol-Myers Squibb (BMS) and Merck & Co. entered into an agreement to co-promote BMS’ diabetes drug, muraglitazar in US. The deal is worth up to US$375 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.